- Home
- TWN vs IPHA Comparison
TWN vs IPHA Comparison
Compare TWN & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TWN
- IPHA
- Stock Information
- Founded
- TWN 1986
- IPHA 1999
- Country
- TWN Hong Kong
- IPHA France
- Employees
- TWN N/A
- IPHA N/A
- Industry
- TWN Trusts Except Educational Religious and Charitable
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- TWN Finance
- IPHA Health Care
- Exchange
- TWN Nasdaq
- IPHA Nasdaq
- Market Cap
- TWN 193.5M
- IPHA 160.1M
- IPO Year
- TWN N/A
- IPHA 2019
- Fundamental
- Price
- TWN $45.51
- IPHA $1.82
- Analyst Decision
- TWN
- IPHA Strong Buy
- Analyst Count
- TWN 0
- IPHA 1
- Target Price
- TWN N/A
- IPHA $11.00
- AVG Volume (30 Days)
- TWN 20.1K
- IPHA 11.8K
- Earning Date
- TWN 01-01-0001
- IPHA 03-27-2025
- Dividend Yield
- TWN 1.10%
- IPHA N/A
- EPS Growth
- TWN N/A
- IPHA N/A
- EPS
- TWN N/A
- IPHA N/A
- Revenue
- TWN N/A
- IPHA $20,831,349.00
- Revenue This Year
- TWN N/A
- IPHA $209.83
- Revenue Next Year
- TWN N/A
- IPHA $83.15
- P/E Ratio
- TWN N/A
- IPHA N/A
- Revenue Growth
- TWN N/A
- IPHA N/A
- 52 Week Low
- TWN $25.22
- IPHA $1.29
- 52 Week High
- TWN $41.51
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- TWN 82.01
- IPHA 39.24
- Support Level
- TWN $44.01
- IPHA $1.71
- Resistance Level
- TWN $44.70
- IPHA $1.92
- Average True Range (ATR)
- TWN 0.58
- IPHA 0.09
- MACD
- TWN 0.09
- IPHA -0.00
- Stochastic Oscillator
- TWN 100.00
- IPHA 37.93
About TWN Taiwan Fund Inc. (The)
Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.